Literature DB >> 12974767

Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.

E V Staikou1, J G Routsias, A A Makri, A Terzoglou, M Sakarellos-Daitsiotis, C Sakarellos, G Panayotou, H M Moutsopoulos, A G Tzioufas.   

Abstract

Calreticulin is a molecular chaperone to newly synthesized polypeptides. Previous studies suggested that calreticulin is probably a protein member of the Ro/La RNP complex. The aims of this study were (a) to investigate whether linear B cell epitopes of the Ro/La RNP complex are bound to calreticulin and (b) if the complex peptide-calreticulin is recognized specifically by anti-Ro autoantibodies. Calreticulin was isolated from either human or pig spleen using a multi-step purification method and found to interact preferentially with biotinylated peptides derived from the sequence of the Ro60 kD 175-184aa(10p) and 216-232aa(17p). The interaction of the peptide-calreticulin complex was favoured by the combination of heat treatment, divalent cations and ATP. La/SSB epitopes did not react with calreticulin. Peptides corresponding to La/SSB epitopes as well as the common epitope of Sm did not interact with calreticulin. Thirty-eight anti-Ro60 KD positive and 23 anti-Ro60 kD negative sera of patients with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) were tested. All anti-Ro60 kD positive sera bound the complex calreticulin-17p, while 95% of the same sera had activity against the complex calreticulin - 10p. Tested individually, calreticulin, pep10p and pep17p presented very low reactivity (8%, 11% and 29%, respectively) against anti-Ro60 kD positive sera. Anti-Ro60 KD negative sera did not exhibit significant reactivity either with calreticulin, 10rho and 17rho or with the complexes calreticulin - 10p and calreticulin-17p (<5%). These results suggest that calreticulin can induce conformation-dependent recognition of the Ro60 kD epitopes, leading eventually to their recognition by autoantibodies. This is the first time that such a relationship is shown between a chaperone protein and fragments of an intracellular autoantigen. This work also provides insights into the understanding of mechanisms for autoantibody production. Furthermore, this association can be proved useful for the development of new sensitive assays for autoantibody detection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974767      PMCID: PMC1808837          DOI: 10.1046/j.1365-2249.2003.02246.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.

Authors:  P Eggleton; F J Ward; S Johnson; M A Khamashta; G R Hughes; V A Hajela; M Michalak; E F Corbett; N A Staines; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway.

Authors:  S Basu; R J Binder; R Suto; K M Anderson; P K Srivastava
Journal:  Int Immunol       Date:  2000-11       Impact factor: 4.823

3.  Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases.

Authors:  D Sánchez; L Tucková; P Sebo; M Michalak; A Whelan; I Sterzl; L Jelínková; E Havrdová; M Imramovská; Z Benes; S Krupicková; H Tlaskalová-Hogenová
Journal:  J Autoimmun       Date:  2000-12       Impact factor: 7.094

4.  Polypeptide binding properties of the chaperone calreticulin.

Authors:  C S Jørgensen; N H Heegaard; A Holm; P Højrup; G Houen
Journal:  Eur J Biochem       Date:  2000-05

Review 5.  Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease.

Authors:  A Rosen; L Casciola-Rosen
Journal:  Cell Death Differ       Date:  1999-01       Impact factor: 15.828

6.  Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins.

Authors:  Y Saito; Y Ihara; M R Leach; M F Cohen-Doyle; D B Williams
Journal:  EMBO J       Date:  1999-12-01       Impact factor: 11.598

7.  Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.

Authors:  S Nair; P A Wearsch; D A Mitchell; J J Wassenberg; E Gilboa; C V Nicchitta
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

8.  High prevalence of antibodies to calreticulin of the IgA class in primary biliary cirrhosis: a possible role of gut-derived bacterial antigens in its aetiology?

Authors:  W Kreisel; A Siegel; A Bahler; C Spamer; E Schiltz; M Kist; G Seilnacht; R Klein; P A Berg; C Heilmann
Journal:  Scand J Gastroenterol       Date:  1999-06       Impact factor: 2.423

9.  Expression and purification of mammalian calreticulin in Pichia pastoris.

Authors:  C Andrin; E F Corbett; S Johnson; M Dabrowska; I D Campbell; P Eggleton; M Opas; M Michalak
Journal:  Protein Expr Purif       Date:  2000-11       Impact factor: 1.650

10.  The conformation of calreticulin is influenced by the endoplasmic reticulum luminal environment.

Authors:  E F Corbett; K M Michalak; K Oikawa; S Johnson; I D Campbell; P Eggleton; C Kay; M Michalak
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

View more
  11 in total

Review 1.  A conspicuous role for B cells In Sjögren's syndrome.

Authors:  Pierre Youinou; Valérie Devauchelle; Pascal Hutin; Rozenn Le Berre; Alain Saraux; Jacques-Olivier Pers
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

2.  Dry eye and designer ophthalmics.

Authors:  Gordon W Laurie; Leslie A Olsakovsky; Brian P Conway; Robert L McKown; Kazuko Kitagawa; Jason J Nichols
Journal:  Optom Vis Sci       Date:  2008-08       Impact factor: 1.973

Review 3.  Stress protein-polypeptide complexes acting as autoimmune triggers.

Authors:  P Eggleton
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

4.  Analysis of parotid glands of primary Sjögren's syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets.

Authors:  E A Stea; J G Routsias; M Samiotaki; G Panayotou; E Papalambros; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

5.  Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein.

Authors:  E A Stathopoulou; J G Routsias; E A Stea; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 6.  Sjögren's syndrome--study of autoantigens and autoantibodies.

Authors:  John G Routsias; Athanasios G Tzioufas
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

7.  Anti-calreticulin immunoglobulin A (IgA) antibodies in refractory coeliac disease.

Authors:  D Sánchez; L Palová-Jelínková; J Felsberg; M Simsová; A Pekáriková; B Pecharová; I Swoboda; T Mothes; C J J Mulder; Z Benes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2008-07-11       Impact factor: 4.330

8.  Calreticulin is a B cell molecular target in some gastrointestinal malignancies.

Authors:  A Pekáriková; D Sánchez; L Palová-Jelínková; M Simsová; Z Benes; I Hoffmanová; P Drastich; I Janatková; T Mothes; H Tlaskalová-Hogenová; L Tucková
Journal:  Clin Exp Immunol       Date:  2009-12-17       Impact factor: 4.330

9.  Ablation of the Chaperone Protein ERdj5 Results in a Sjögren's Syndrome-Like Phenotype in Mice, Consistent With an Upregulated Unfolded Protein Response in Human Patients.

Authors:  Eirini Apostolou; Petros Moustardas; Takao Iwawaki; Athanasios G Tzioufas; Giannis Spyrou
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

10.  ER Stress Proteins in Autoimmune and Inflammatory Diseases.

Authors:  Daisuke Morito; Kazuhiro Nagata
Journal:  Front Immunol       Date:  2012-03-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.